Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome

被引:210
|
作者
Rassen, Jeremy A. [1 ]
Choudhry, Niteesh K.
Avorn, Jerry
Schneeweiss, Sebastian
机构
[1] Harvard Univ, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med,Med Sch, Boston, MA 02120 USA
基金
美国国家卫生研究院; 美国医疗保健研究与质量局;
关键词
clopidogrel; drugs; myocardial infarction; platelets; proton pump inhibitors; revascularization; ACUTE MYOCARDIAL-INFARCTION; ST-SEGMENT ELEVATION; ANTIPLATELET ACTION; CONTROLLED TRIAL; ASPIRIN; THERAPY; RISK; RESISTANCE; EVENTS; DRUGS;
D O I
10.1161/CIRCULATIONAHA.109.873497
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Recent studies have raised concerns about the reduced efficacy of clopidogrel when used concurrently with proton pump inhibitors (PPIs), but those studies may have overestimated the risk. Methods and Results-We studied the potential for increased risk of adverse cardiovascular events among users of clopidogrel with versus without concurrent use of PPIs in 3 large cohorts of patients >= 65 years of age, treated between 2001 and 2005. All patients had undergone percutaneous coronary intervention or had been hospitalized for acute coronary syndrome in Pennsylvania, New Jersey, or British Columbia, and subsequently had initiated treatment with clopidogrel. We recorded myocardial infarction hospitalization, death, and revascularization among PPI users and nonusers. We assessed our primary end point of myocardial infarction hospitalization or death using cohort-specific and pooled regression analyses. We entered 18 565 clopidogrel users into our analysis. On a pooled basis, 2.6% of those who also initiated a PPI versus 2.1% of PPI nonusers had a myocardial infarction hospitalization; 1.5% versus 0.9% died; and 3.4% versus 3.1% underwent revascularization. The propensity score-adjusted rate ratio for the primary end point of myocardial infarction or death was 1.22 (95% confidence interval, 0.99 to 1.51); for death, 1.20 (95% confidence interval, 0.84 to 1.70); and for revascularization, 0.97 (95% confidence interval, 0.79 to 1.21). Matched analyses generally yielded similar results. Conclusions-Although point estimates indicated a slightly increased risk of myocardial infarction hospitalization or death in older patients initiating both clopidogrel and a PPI, we did not observe conclusive evidence of a clopidogrel-PPI interaction of major clinical relevance. Our data suggest that if this effect exists, it is unlikely to exceed a 20% risk increase. (Circulation. 2009; 120: 2322-2329.)
引用
收藏
页码:2322 / U34
页数:11
相关论文
共 50 条
  • [31] THE CARDIOVASCULAR OUTCOMES ASSOCIATED WITH CONCOMITANT USE OF CLOPIDOGREL AND PROTON PUMP INHIBITORS IN PATIENTS OF ACUTE CORONARY SYNDROME IN TAIWAN - A POPULATION-BASED COHORT STUDY
    Gau, C.
    Lin, C.
    Shen, L.
    Lin, F.
    Bai, C.
    Wang, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S8 - S9
  • [32] Prevalence and outcomes of prasugrel versus clopidogrel in patients with and without diabetes following percutaneous coronary intervention for acute coronary syndrome
    Faggioni, M.
    Chandrasekhar, J.
    Baber, U.
    Sartori, S.
    Aquino, M.
    Rao, S.
    Weintraub, W.
    Effron, M.
    Baker, B.
    Danias, G.
    Pocock, S.
    Kapadia, S.
    Toma, C.
    Mehran, R.
    Henry, T.
    EUROPEAN HEART JOURNAL, 2016, 37 : 379 - 379
  • [33] Impact of Coronary Dominance on In-Hospital Outcomes After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome
    Kuno, Toshiki
    Numasawa, Yohei
    Miyata, Hiroaki
    Takahashi, Toshiyuki
    Sueyoshi, Kouichirnu
    Ohki, Takahiro
    Negishi, Koji
    Kawamura, Akio
    Kohsaka, Shun
    Fukuda, Keiichi
    CIRCULATION, 2013, 128 (22)
  • [34] Impact of Coronary Dominance on In-Hospital Outcomes after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome
    Kuno, Toshiki
    Numasawa, Yohei
    Miyata, Hiroaki
    Takahashi, Toshiyuki
    Sueyoshi, Koichiro
    Ohki, Takahiro
    Negishi, Koji
    Kawamura, Akio
    Kohsaka, Shun
    Fukuda, Keiichi
    PLOS ONE, 2013, 8 (08):
  • [35] Using ultrasound radiomics to forecast adverse cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention
    Wu, Shutian
    Liu, Biaohu
    Fan, Haiyun
    Zhong, Yuxin
    Yang, You
    Yao, Aling
    ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES, 2024, 41 (08):
  • [36] Ticagrelor versus clopidogrel in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention
    Li, Yuzhuo
    Li, Jing
    Qiu, Miaohan
    Ma, Sicong
    Na, Kun
    Li, Xiaoying
    Qi, Zizhao
    Chen, Sanbao
    Li, Yi
    Han, Yaling
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2022, 99 : 1395 - 1402
  • [37] Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome
    Ho, P. Michael
    Maddox, Thomas M.
    Wang, Li
    Fihn, Stephan D.
    Jesse, Robert L.
    Peterson, Eric D.
    Rumsfeld, John S.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (09): : 937 - 944
  • [38] Efficacy and safety of proton pump inhibitors combined with clopidogrel in patients undergoing percutaneous coronary intervention: a meta-analysis
    Han, Yao-Yao
    Li, Zheng-Xiang
    Duan, Rong
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2021, 22 (01) : 167 - 174
  • [39] Proton Pump Inhibitors Increase Major Adverse Cardiac Events Among Post Percutaneous Coronary Intervention Patients on Clopidogrel
    Ching, Gilbert
    Li, Dadong
    McKay, Raymond
    Mather, Jeffrey
    Lundbye, Justin
    CIRCULATION, 2009, 120 (18) : S936 - S937
  • [40] Effects of Peri-Interventional High Clopidogrel Dose on the Outcomes of Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients With Low Response to Clopidogrel
    Jia Xinwei
    Fu Xianghua
    Gu Xinshun
    Pan Huanjun
    Fan Weize
    Zhang Jing
    Wang Zhanqi
    Wu Weili
    Li Shiqiang
    Hao Guozhen
    CIRCULATION, 2010, 122 (02) : E42 - E42